In oral solid-dose manufacturing, (2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)thiobutyramide is first screened for excipient compatibility under 40 °C/75% RH for 1 month and 3 months, with binary samples assessed by HPLC for related substances. Direct compression is restricted to API lots that exhibit a Hausner ratio below 1.25 and a Carr index below 25%; if these thresholds are exceeded, roller compaction is used. A representative high-dose formulation contains 20% to 45% w/w API, 25% to 50% microcrystalline cellulose, 20% to 40% anhydrous lactose or mannitol, 2% to 5% crospovidone, 0.2% to 0.5% colloidal silicon dioxide, and 0.5% to 1.0% magnesium stearate. The dry granulation step is run on a roller compactor at roll force 6 kN/cm to 12 kN/cm, roll speed 2 rpm to 6 rpm, and screen opening 0.8 mm to 1.25 mm to produce ribbon density 0.8 g/cm³ to 1.2 g/cm³ and milled granule D50 150 µm to 350 µm. Tablets are compressed on a rotary press at 8 kN to 18 kN main compression force, 30 rpm to 60 rpm turret speed, and coated with an aqueous film coat to 2% to 4% weight gain. The finished film-coated tablet is controlled by USP <905> for content uniformity, USP <701> for disintegration, USP <711> Apparatus II for dissolution, and USP <467> for residual solvents, with impurity reporting aligned to ICH Q3B.

What Limits Capsule Fill Uniformity at Encapsulation Speeds Above 40,000 Capsules per Hour?

At high capsule filling rates, weight variation is controlled less by the final blend bulk density and more by the interaction between powder rheology and the dosing chamber design of the encapsulator. For this triazole API, dry powder filling into hard gelatin or HPMC capsules is performed on a dosing-disc or dosator machine, with fill weight 250 mg to 400 mg for size 0 or size 1 capsules. The formulation comprises 10% to 25% API, 50% to 75% lactose monohydrate or mannitol, 10% to 20% pregelatinized starch, 2% to 4% sodium starch glycolate, 0.2% to 0.5% fumed silica, and 1% to 2% sodium stearyl fumarate. Because the thioamide moiety can adsorb to metallic surfaces under low-humidity triboelectric charging, the encapsulation suite is maintained at 40% to 50% RH and 20 °C to 25 °C. Fill weight RSD is monitored by in-process checkweighing and maintained at ≤ 2.0%. Content uniformity is confirmed by USP <905> with acceptance value ≤ 15, and dissolution by USP <711> Apparatus II. The capsule shell itself is subjected to microbial limits per USP <61>/USP <62>; the final dosage form is a hard capsule for immediate oral release.

Granule Growth, Binder Dispersal, and Fluid-Bed Drying Parameters

Granule-based dosage forms are prepared by top-spray fluid-bed granulation when a sachet or reconstitutable oral suspension is required. The API is loaded at 5% to 20% w/w onto a bulking platform of sucrose, mannitol, or xylitol at 40% to 70%, with sodium croscarmellose 2% to 6% as disintegrant, povidone K30 1% to 4% as binder, and a non-reducing flavor system. The binder solution is sprayed under top-spray conditions at inlet air 55 °C to 70 °C, product temperature 30 °C to 40 °C, spray rate 150 g/min to 300 g/min for a 10 kg batch, atomizing air 1.5 bar to 2.5 bar, and final drying to loss-on-drying NMT 2.0%. Granule size is controlled through sieve cuts at 150 µm and 500 µm, with oversize milled through a conical mill and fines recycled. The finished granules are filled into single-dose sachets or bottles; the sachet product is evaluated by USP <905>, USP <711> for suspension dissolution, USP <701> for suspension dispersibility, and water activity is maintained below 0.60 to reduce hydrolytic degradation of the thioamide function.

For injectable solution presentation, the API is formulated as a clear, sterile solution for intravenous or intramuscular use only after a solubility screen across pH and co-solvent conditions demonstrates adequate recoverable concentration. The vehicle is typically composed of sulfobutylether-β-cyclodextrin at 5% to 15% w/v, citrate buffer 10 mM to 25 mM at pH 3.0 to 4.5, and water for injection to final volume, with the API concentration commonly in the range of 0.5% to 2.0% w/v. Oxygen-sensitive thioamide degradation is controlled by nitrogen sparging and by limiting dissolved oxygen to < 1 ppm before filling; the solution is filtered through a 0.22 µm PVDF or PES membrane under aseptic conditions. Terminal sterilization by autoclave is not assumed for a triazole thioamide API without thermal stress data, so aseptic processing in ISO 5 is used, and the fill is performed on a piston-pump vial line at fill volume 5 mL to 50 mL. Release testing includes USP <788> particulate matter, USP <85> bacterial endotoxins, USP <71> sterility, and USP <790> visible particulates. The finished product is a sterile solution for injection, with extractables and leachables assessed per USP <1663> and USP <1664> because the cyclodextrin vehicle may alter the partitioning of stopper leachables.

When Lyophilization Is Required Because Terminal Sterilization Is Not Feasible

A lyophilized injectable format becomes necessary when solution-state stability data show unacceptable hydrolytic degradation of the thioamide group at ambient or refrigerated storage. The pre-lyophilization solution contains the API at a strength that yields 10 mg/vial to 50 mg/vial after drying, with mannitol or glycine 2% to 6% w/v as crystalline bulking agent and trehalose or sucrose 2% to 4% w/v as lyoprotectant, in a buffer of pH 3.0 to 4.5. The solution is filtered through a 0.22 µm membrane and filled into molded or tubing vials under ISO 5 conditions. Freezing is conducted at shelf -40 °C to -45 °C, followed by annealing at -15 °C to -20 °C for 2 h to 4 h when mannitol crystallization is required. Primary drying is run at shelf temperature -25 °C to -10 °C with chamber pressure 100 mTorr to 200 mTorr, while product temperature is maintained below the collapse temperature determined by freeze-drying microscopy. Secondary drying is conducted at 20 °C to 30 °C for 6 h to 12 h until cake moisture is NMT 2.0% by USP <921>. The final lyophilized powder for injection is inspected for cake collapse, meltback, and cosmetic defects, and is tested for sterility, bacterial endotoxins, reconstitution time < 2 min, and particulate matter per USP <788>.

Sterile filtration recovery should be confirmed when infusion bags are prepared at concentrations below 0.5 mg/mL

Point-of-use dilution of the injectable product into sodium chloride 0.9% or dextrose 5% infusion bags requires an adsorption and compatibility study because low API concentrations can reduce recoverable content through binding to PVC, polyolefin, or sterilizing filter membranes. A compounding and administration protocol typically specifies dilution into a polyolefin or DEHP-free PVC container at final concentration 0.1 mg/mL to 0.5 mg/mL, with an inline 0.22 µm filter or 1.2 µm air-venting administration set. Chemical stability is monitored at 2–8 °C and 25 °C over 24 h to 48 h, with pH drift and particulate formation evaluated per USP <788>. Adsorptive loss to nylon filters is assessed as a separate failure mode because triazole and thioamide functional groups can interact with polyamide membrane surfaces. The resulting ready-to-use infusion is controlled by hospital pharmacy compounding standards such as USP <797>, and the dose is administered only after confirmation that endotoxin limits per USP <85> are not exceeded by the compounded bag. Published data for this specific configuration is limited, so site-specific in-use stability protocols are required before clinical deployment.